Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:IMGO

Imago BioSciences (IMGO) Stock Price, News & Analysis

Imago BioSciences logo

About Imago BioSciences Stock (NASDAQ:IMGO)

Key Stats

Today's Range
$36.01
$36.01
50-Day Range
$35.78
$36.01
52-Week Range
$11.56
$36.09
Volume
N/A
Average Volume
171,367 shs
Market Capitalization
$1.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Receive IMGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imago BioSciences and its competitors with MarketBeat's FREE daily newsletter.

IMGO Stock News Headlines

Why I'm telling friends to avoid gold stocks
Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
Merck: Better Times Ahead On Approvals And Outlook
Clarus Lifesciences III, L.P.'s Net Worth
Anixa Biosciences Inc ANIX
See More Headlines

IMGO Stock Analysis - Frequently Asked Questions

Imago BioSciences, Inc. (NASDAQ:IMGO) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.10.

Imago BioSciences (IMGO) raised $105 million in an initial public offering (IPO) on Friday, July 16th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share.

Based on aggregate information from My MarketBeat watchlists, some other companies that Imago BioSciences investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Advanced Micro Devices (AMD) and Alphabet (GOOG).

Company Calendar

Last Earnings
11/10/2021
Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMGO
Fax
N/A
Employees
27
Year Founded
N/A

Profitability

Net Income
$-42,310,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.40 per share

Miscellaneous

Free Float
28,783,000
Market Cap
$1.22 billion
Optionable
Not Optionable
Beta
2.82
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:IMGO) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners